Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose IL-2 in Metastatic Renal Cell Carcinoma After Low-Dose Failure
NCT00080977Phase 2Unknown
- Sponsor
- Levine Cancer Institute
- Start
- Jun 1998
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in renal cell carcinoma (RCC), sponsored by Levine Cancer Institute. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00080977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080977.